Updated Correlative Analysis from CARTITUDE-1, a Phase 1b/2 Study of Cilta-cel, a BCMA-Targeted CAR-T Cell Therapy in Relapsed &/or Refractory Multiple Myeloma

Time: 1:30 pm
day: Day Two

Details:

  • Cilta-cel is a differentiated BCMA-specific CART cell therapy
  • Cilta-cel clinical responses are independent of CART cells expansion/persistence or BCMA expression

Speakers: